detectnet Drug Patent Profile
✉ Email this page to a colleague
When do Detectnet patents expire, and when can generic versions of Detectnet launch?
Detectnet is a drug marketed by Radiomedix and is included in one NDA. There are three patents protecting this drug.
This drug has eleven patent family members in six countries.
The generic ingredient in DETECTNET is copper cu-64 dotatate. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the copper cu-64 dotatate profile page.
DrugPatentWatch® Generic Entry Outlook for Detectnet
Detectnet was eligible for patent challenges on September 3, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 3, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for detectnet?
- What are the global sales for detectnet?
- What is Average Wholesale Price for detectnet?
Summary for detectnet
International Patents: | 11 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 1 |
Drug Prices: | Drug price information for detectnet |
What excipients (inactive ingredients) are in detectnet? | detectnet excipients list |
DailyMed Link: | detectnet at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for detectnet
Generic Entry Date for detectnet*:
Constraining patent/regulatory exclusivity:
FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for detectnet
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Wisconsin, Madison | Phase 1 |
Pharmacology for detectnet
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for detectnet
detectnet is protected by three US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of detectnet is ⤷ Sign Up.
This potential generic entry date is based on FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting detectnet
Pet tracer for imaging of neuroendocrine tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
PET tracer for imaging of neuroendocrine tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
PET tracer for imaging of neuroendocrine tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
FDA Regulatory Exclusivity protecting detectnet
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Radiomedix | DETECTNET | copper cu-64 dotatate | SOLUTION;INTRAVENOUS | 213227-001 | Sep 3, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Radiomedix | DETECTNET | copper cu-64 dotatate | SOLUTION;INTRAVENOUS | 213227-001 | Sep 3, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Radiomedix | DETECTNET | copper cu-64 dotatate | SOLUTION;INTRAVENOUS | 213227-001 | Sep 3, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Radiomedix | DETECTNET | copper cu-64 dotatate | SOLUTION;INTRAVENOUS | 213227-001 | Sep 3, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Radiomedix | DETECTNET | copper cu-64 dotatate | SOLUTION;INTRAVENOUS | 213227-001 | Sep 3, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for detectnet
See the table below for patents covering detectnet around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2750717 | TRACEUR TEP POUR L'IMAGERIE DE TUMEURS NEURO-ENDOCRINES (PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS) | ⤷ Sign Up |
Denmark | 3536346 | ⤷ Sign Up | |
Spain | 2842998 | ⤷ Sign Up | |
European Patent Office | 3536346 | TRACEUR TEP POUR L'IMAGERIE DE TUMEURS NEURO-ENDOCRINES (PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS) | ⤷ Sign Up |
Spain | 2732823 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |